The impact of pharmacological agents on neuroinflammation in neurodegenerative diseases

Neuroinflammation plays a crucial role in the progression of age-related and chronic neurological diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. This review examines the mechanisms of neuroinflammation by focusing on microglial and astrocyte activati...

Full description

Saved in:
Bibliographic Details
Main Authors: Sharma Anurag, Khan Zoya, Nath Rajendra, Dixit Rakesh Kumar
Format: Article
Language:English
Published: Sciendo 2025-06-01
Series:Acta Marisiensis - Seria Medica
Subjects:
Online Access:https://doi.org/10.2478/amma-2025-0018
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849416693296660480
author Sharma Anurag
Khan Zoya
Nath Rajendra
Dixit Rakesh Kumar
author_facet Sharma Anurag
Khan Zoya
Nath Rajendra
Dixit Rakesh Kumar
author_sort Sharma Anurag
collection DOAJ
description Neuroinflammation plays a crucial role in the progression of age-related and chronic neurological diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. This review examines the mechanisms of neuroinflammation by focusing on microglial and astrocyte activation, key signaling pathways such as NFκB and JAK/STAT, and metabolic disturbances that modulate inflammatory processes. Pharmacological treatments, including NSAIDs, minocycline, and statins, have demonstrated some efficacy; however, their therapeutic potential is often limited by suboptimal drug delivery to the target regions and variability in patient response. The review further highlights innovative pharmacologic strategies that modulate microglial function, moving beyond the outdated M1/M2 polarization models and embracing a more dynamic view of microglial plasticity, where activation depends on the local environment and disease context. Furthermore, state-of-the-art computational and experimental drug discovery techniques are leveraged to explore novel therapies. Additionally, natural compounds such as curcumin, resveratrol, and nootropics have shown potential in modulating neuroinflammation through diverse molecular pathways. Compounds were selected based on their demonstrated clinical relevance and ability to modulate neuroinflammation through well-defined molecular mechanisms. Excluded compounds like melatonin and cannabidiol were omitted due to limited clinical data on their efficacy and concerns about off-target effects.
format Article
id doaj-art-1cfcba4e8d344053b07ca9089c6b4c78
institution Kabale University
issn 2668-7763
language English
publishDate 2025-06-01
publisher Sciendo
record_format Article
series Acta Marisiensis - Seria Medica
spelling doaj-art-1cfcba4e8d344053b07ca9089c6b4c782025-08-20T03:33:07ZengSciendoActa Marisiensis - Seria Medica2668-77632025-06-017129510510.2478/amma-2025-0018The impact of pharmacological agents on neuroinflammation in neurodegenerative diseasesSharma Anurag0Khan Zoya1Nath Rajendra2Dixit Rakesh Kumar31Department of Pharmacology and Therapeutics, King George’s Medical University, Lucknow, Uttar Pradesh, India1Department of Pharmacology and Therapeutics, King George’s Medical University, Lucknow, Uttar Pradesh, India1Department of Pharmacology and Therapeutics, King George’s Medical University, Lucknow, Uttar Pradesh, India1Department of Pharmacology and Therapeutics, King George’s Medical University, Lucknow, Uttar Pradesh, IndiaNeuroinflammation plays a crucial role in the progression of age-related and chronic neurological diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. This review examines the mechanisms of neuroinflammation by focusing on microglial and astrocyte activation, key signaling pathways such as NFκB and JAK/STAT, and metabolic disturbances that modulate inflammatory processes. Pharmacological treatments, including NSAIDs, minocycline, and statins, have demonstrated some efficacy; however, their therapeutic potential is often limited by suboptimal drug delivery to the target regions and variability in patient response. The review further highlights innovative pharmacologic strategies that modulate microglial function, moving beyond the outdated M1/M2 polarization models and embracing a more dynamic view of microglial plasticity, where activation depends on the local environment and disease context. Furthermore, state-of-the-art computational and experimental drug discovery techniques are leveraged to explore novel therapies. Additionally, natural compounds such as curcumin, resveratrol, and nootropics have shown potential in modulating neuroinflammation through diverse molecular pathways. Compounds were selected based on their demonstrated clinical relevance and ability to modulate neuroinflammation through well-defined molecular mechanisms. Excluded compounds like melatonin and cannabidiol were omitted due to limited clinical data on their efficacy and concerns about off-target effects.https://doi.org/10.2478/amma-2025-0018neuroinflammationneurodegenerative diseasespharmacological agentsneuroprotectioninflammatory pathwaystherapeutic targets
spellingShingle Sharma Anurag
Khan Zoya
Nath Rajendra
Dixit Rakesh Kumar
The impact of pharmacological agents on neuroinflammation in neurodegenerative diseases
Acta Marisiensis - Seria Medica
neuroinflammation
neurodegenerative diseases
pharmacological agents
neuroprotection
inflammatory pathways
therapeutic targets
title The impact of pharmacological agents on neuroinflammation in neurodegenerative diseases
title_full The impact of pharmacological agents on neuroinflammation in neurodegenerative diseases
title_fullStr The impact of pharmacological agents on neuroinflammation in neurodegenerative diseases
title_full_unstemmed The impact of pharmacological agents on neuroinflammation in neurodegenerative diseases
title_short The impact of pharmacological agents on neuroinflammation in neurodegenerative diseases
title_sort impact of pharmacological agents on neuroinflammation in neurodegenerative diseases
topic neuroinflammation
neurodegenerative diseases
pharmacological agents
neuroprotection
inflammatory pathways
therapeutic targets
url https://doi.org/10.2478/amma-2025-0018
work_keys_str_mv AT sharmaanurag theimpactofpharmacologicalagentsonneuroinflammationinneurodegenerativediseases
AT khanzoya theimpactofpharmacologicalagentsonneuroinflammationinneurodegenerativediseases
AT nathrajendra theimpactofpharmacologicalagentsonneuroinflammationinneurodegenerativediseases
AT dixitrakeshkumar theimpactofpharmacologicalagentsonneuroinflammationinneurodegenerativediseases
AT sharmaanurag impactofpharmacologicalagentsonneuroinflammationinneurodegenerativediseases
AT khanzoya impactofpharmacologicalagentsonneuroinflammationinneurodegenerativediseases
AT nathrajendra impactofpharmacologicalagentsonneuroinflammationinneurodegenerativediseases
AT dixitrakeshkumar impactofpharmacologicalagentsonneuroinflammationinneurodegenerativediseases